Table 1.
Clinical trials with ATP-competitive FAK inhibitors
| FAK inhibitor name |
Combination agents | Cancer type | Phase | Status | NCI identifier |
|---|---|---|---|---|---|
|
VS-6062 (PF00562271) |
/ | Pancreatic, head and neck, prostatic neoplasms | Phase I | Completed [45] | NCT00666926 |
|
VS-6063 (Defactinib) |
/ | Non-hematologic malignancies | Phase I | Completed [46] | NCT00787033 |
| / | Non-hematologic cancers | Phase I | Completed | NCT01943292 | |
| / | Healthy subjects | Phase I | Completed | NCT02913716 | |
| / | Non-small cell lung cancer | Phase II | Completed [47] | NCT01951690 | |
|
Paclitaxel, Defactinib |
Ovarian cancer | Phase I | Completed | NCT01778803 | |
| RO5126766 |
NSCLC, LGSOC Colorectal cancer |
Phase I | Recruiting | NCT03875820 | |
| VS-6766 | Ovarian cancer | Phase II | Recruiting | NCT04625270 | |
| VS-6766 | Non-small cell lung cancer | Phase II | Recruiting [48] | NCT04620330 | |
| VS-6766 | Metastatic uveal melanoma | Phase II | Recruiting | NCT04720417 | |
| VS-6766 | Ovarian cancer | Phase II | Recruiting | NCT04625270 | |
| Pembrolizumab |
Pancreatic ductal Adenocarcinoma |
Phase II | Recruiting | NCT03727880 | |
| Pembrolizumab | Mesothelioma |
Phase I Phase II |
Recruiting | NCT02758587 | |
|
Paclitaxel, Carboplatin |
Ovarian cancer |
Phase I Phase II |
Recruiting | NCT03287271 | |
| / | Advanced lymphoma | Phase II | Active, not recruiting | NCT04439331 | |
| PembrolizumabGemcitabine | Advanced solid tumors | Phase I | Active, not recruiting | NCT02546531 | |
| Pembrolizumab | Malignant pleural mesothelioma | Phase I | Withdrawn | NCT04201145 | |
| Avelumab | Epithelial ovarian cancer | Phase I | Terminated | NCT02943317 [49] | |
| / | Malignant pleural mesothelioma | Phase II | Terminated | NCT02004028 | |
| Placebo | Malignant pleural mesothelioma | Phase II | Terminated [50] | NCT01870609 | |
| GSK2256098 | Trametinib |
Pancreatic cancer Adenocarcinoma |
Phase II | Recruiting | NCT02428270 |
| Trametinib | Neoplasms | Phase I | Completed [51] | NCT01938443 | |
| Placebo | Healthy volunteers | Phase I | Completed | NCT00996671 | |
| / | Solid tumors | Phase I | Completed [52] | NCT01138033 | |
| Vismodegib | Meningioma | Phase II | Suspended | NCT02523014 | |
|
PND-1186 (VS-4718) |
Nab-Paclitaxel, Gemcitabine |
Pancreatic cancer | Phase I | Terminated | NCT02651727 |
| / | Non-hematologic cancers | Phase I | Terminated | NCT01849744 | |
| / | Relapsed or refractory acute myeloid leukemia | Phase I | Withdrawn | NCT02215629 [53] | |
|
IN10018 (BI-853520) |
Cobimetinib | Metastatic melanoma | Phase I | Recruiting | NCT04109456 |
| Traditional chemotherapy |
HGSOC Oviduct cancer |
Phase I | Recruiting | CTR20200913 | |
| Docetaxel | Gastric cancer | Phase I | Recruiting | CTR20192715 | |
| / | Neoplasms | Phase I | Completed [54] | NCT01905111 | |
| / | Neoplasms | Phase I | Completed | NCT01335269 |